A Phase 2 interventional study of Samatasvir and Simeprevir in Chronic Hepatitis C Virus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-04-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing simeprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. Simeprevir · Hepatitis C, Chronic.
Among the 21 studies testing simeprevir in Hepatitis C, Chronic, this one is the 6th largest by enrollment, is one of 5 that started in 2013, is one of 9 in phase 2, and was the 9th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 21 studies testing simeprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
Simeprevir: first FDA approval 2013 (OLYSIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2013.
This study's enrollment of 143 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 93 across the 21 interventional studies. Of the 20 that completed or were terminated, 13 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
110 studies in Hepatitis C, Chronic by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 106 finished, 81 (76%) have results posted.
Among the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc, this one is the 31st largest by enrollment of the 72 interventional ones that give a count, is one of 8 that started in 2013, is one of 16 in phase 2, and was the 98th registered.
Merck & Co., Inc’s Hepatitis C, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing simeprevir in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 110 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Parts A and B of this study are designed to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of samatasvir and simeprevir when administered in combination with ribavirin (RBV) for 12 weeks in treatment-naïve, Genotype (GT) 1b, 4 and 6 hepatitic C virus (HCV)-infected participants.
Part C of this study is designed to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of samatasvir, simeprevir, TMC647055 and ritonavir (RTV) when administered in combination with or without RBV for 12 weeks in treatment-naïve or interferon/RBV-treatment relapsed, GT 1a and 1b HCV-infected participants.
Part A of this study is randomized and double-blind. Parts B and C are randomized and open-label.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Participants with genotype 1b or 4 received samatasvir 50 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Biological: Pegylated interferon (Peg-IFN) · Other: Samatasvir matching placebo
Part A: Participants with genotype 1b or 4 received samatasvir 100 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Biological: Pegylated interferon (Peg-IFN) · Other: Samatasvir matching placebo
Part A: Participants with genotype 1b or 4 received samatasvir 150 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Biological: Pegylated interferon (Peg-IFN)
Part B: Participants with genotype 1b or 4 received samatasvir 25 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Biological: Pegylated interferon (Peg-IFN)
Part B: Participants with genotype 1b or 4 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Biological: Pegylated interferon (Peg-IFN)
Part B: Participants with Genotype 6 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Biological: Pegylated interferon (Peg-IFN)
Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily plus RTV 30 mg once daily for 12 weeks
Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Drug: TMC647055 · Drug: Ritonavir (RTV) · Biological: Pegylated interferon (Peg-IFN)
Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily, plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Drug: TMC647055 · Drug: Ritonavir (RTV) · Biological: Pegylated interferon (Peg-IFN)
Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.
Simeprevir will be supplied as 75 and 150 mg oral capsules.
Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.
TMC647055 will be supplied as 150 mg oral capsules.
Ritonavir will be supplied as 80 mg/mL oral solution.
Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.
Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.
Percentage of participants who experienced an adverse event (AE)
Time frame: Up to approximately 95 weeks
Percentage of participants who experienced a serious adverse event (SAE)
Time frame: Up to approximately 95 weeks
Percentage of participants who experienced a Grade 1-4 laboratory abnormality
Time frame: Up to 66 weeks
Percentage of participants who experienced sustained virologic response 4 weeks after the end of treatment (SVR4)
Time frame: Up to 16 weeks
Percentage of participants who experienced rapid virologic response (RVR)
Time frame: Week 4
Percentage of participants who experienced early virologic response (EVR)
Time frame: Week 12
Percentage of participants who experienced sustained virologic response 8 weeks after the end of treatment (SVR8)
Time frame: Up to 20 weeks
Percentage of participants who experienced sustained virologic response 12 weeks after the end of treatment (SVR12)
Time frame: Up to 24 weeks
Percentage of participants who experienced sustained virologic response 24 weeks after the end of treatment (SVR24)
Time frame: Up to 36 weeks
Pharmacokinetic Parameter:Area under the concentration-time curve from time zero to t
Time frame: Days 1, 4, 7, 10, 14, 21, 28, 42, 56 and 84
Pharmacokinetic Parameter: Maximum observed drug concentration (Cmax)
Time frame: Days 1, 4, 7, 10, 14, 21, 28, 42, 56 and 84
Pharmacokinetic Parameter: Trough drug concentration (Ctrough)
Time frame: Days 1, 4, 7, 10, 14, 21, 28, 42, 56 and 84
No study locations are listed for this record.
The record gives a start of Mar 2013, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Samatasvir · Simeprevir · Ribavirin